Viridian Therapeutics, Inc. (MGEN) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Innoviva, Inc.

Collegium Pharmaceutical, Inc.

Amneal Pharmaceuticals, Inc.

Ardelyx, Inc.

Viridian Therapeutics, Inc.

NewAmsterdam Pharma Co. NV

Arcturus Therapeutics Holdings, Inc.

REGENXBIO, Inc.

Pharvaris NV

POINT Biopharma Global, Inc.

Intercept Pharmaceuticals, Inc.

Why is Viridian Therapeutics, Inc. ?

Flat results in Mar 26

OPERATING CASH FLOW(Y) Lowest at USD -303.86 MM
ROCE(HY) Lowest at -55.17%
DEBTORS TURNOVER RATIO(HY) Lowest at 0 times

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 10.87%, its profits have fallen by -26.9%

Underperformed the market in the last 1 year

The stock has generated a return of 10.87% in the last 1 year, much lower than market (S&P 500) returns of 25.41%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Viridian Therapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Viridian Therapeutics, Inc.

10.87%

0.51

71.05%

S&P 500

25.41%

1.92

13.25%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

132.18%

EBIT Growth (5y)

-247.64%

EBIT to Interest (avg)

-106.87

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.02

Sales to Capital Employed (avg)

0.02

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.88

EV to EBIT

-5.44

EV to EBITDA

-5.46

EV to Capital Employed

-19.41

EV to Sales

27.88

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-44.80%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Bullish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Bullish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

14What is working for the Company

NET SALES(HY)

At USD 0.27 MM has Grown at 89.58%

NET PROFIT(HY)

Higher at USD -213.71 MM

RAW MATERIAL COST(Y)

Fallen by -103.86% (YoY

CASH AND EQV(HY)

Highest at USD 1,636.83 MM

DEBT-EQUITY RATIO (HY)

Lowest at -111.79 %

-21What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD -303.86 MM

ROCE(HY)

Lowest at -55.17%

DEBTORS TURNOVER RATIO(HY)

Lowest at 0 times

INTEREST(Q)

Highest at USD 3.46 MM

PRE-TAX PROFIT(Q)

Fallen at -29.36%

NET PROFIT(Q)

Lowest at USD -112.43 MM

Here's what is working for Viridian Therapeutics, Inc.

Net Sales

At USD 0.27 MM has Grown at 89.58%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very positive

Net Sales (USD MM)

Cash and Eqv

Highest at USD 1,636.83 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at -111.79 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by -103.86% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Viridian Therapeutics, Inc.

Operating Cash Flow

Lowest at USD -303.86 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Interest

Highest at USD 3.46 MM

in the last five periods and Increased by 5.48% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Pre-Tax Profit

Fallen at -29.36%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -112.43 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Net Profit

Fallen at -29.36%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Debtors Turnover Ratio

Lowest at 0 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio